Launch of AMBLor Test Enables Risk Stratification in Early-Stage Melanoma
Source: Onc Live, February 2023
Avero Diagnostics has launched AMBLor, a first-of-its-kind laboratory test for the identification of early-stage melanoma at low risk of progression. The company developed the test after licensing the underpinning technology from AMLo Biosciences in September 2022.
“Patients often experience a huge amount of anxiety relating to a melanoma diagnosis, and AMBLor is the first test available that offers a way to provide accurate, clinically validated prognostic information relating to tumor progression. With the current guidance recommending the same treatment regimen for all early-stage melanoma patients, AMBLor will enable physicians to provide a more personalized approach to disease management and will provide patients peace of mind if identified as low-risk of metastasis,” Maureen Basius, DO, anatomic and clinical pathology specialist, said in a press release.
Skin cancer is the most common cancer, and the incidence of the most severe skin cancer, melanoma, has been increasing over recent decades. Approximately 100,000 new melanoma cases are diagnosed every year, of which approximately 7500 will be fatal, according to the American Cancer Society.2